503 related articles for article (PubMed ID: 19147692)
1. Cytoreductive nephrectomy in metastatic clear-cell renal cell carcinoma: perspectives in the tyrosine kinase inhibitor era.
Biswas S; Kelly J; Eisen T
Oncologist; 2009 Jan; 14(1):52-9. PubMed ID: 19147692
[TBL] [Abstract][Full Text] [Related]
2. Surgical outcomes and complications associated with presurgical tyrosine kinase inhibition for advanced renal cell carcinoma (RCC).
Harshman LC; Yu RJ; Allen GI; Srinivas S; Gill HS; Chung BI
Urol Oncol; 2013 Apr; 31(3):379-85. PubMed ID: 21353796
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma treated with first-line sunitinib: a European multiinstitutional study.
Bamias A; Tzannis K; Papatsoris A; Oudard S; Beuselinck B; Escudier B; Liontos M; Elaidi TR; Chrisofos M; Stravodimos K; Anastasiou I; Mitropoulos D; Deliveliotis C; Constantinides C; Dimopoulos MA; Bamia C
Clin Genitourin Cancer; 2014 Oct; 12(5):373-83. PubMed ID: 24819319
[TBL] [Abstract][Full Text] [Related]
4. [CYTOREDUCTIVE NEPHRECTOMY IN METASTATIC RENAL CELL CANCER].
Nosov AK; Novik AV; Vorobiev AV; Samartseva EE; Reva SA; Baldueva IA; Lushina PA
Vopr Onkol; 2015; 61(3):494-8. PubMed ID: 26242167
[TBL] [Abstract][Full Text] [Related]
5. [Interdisciplinary recommendations on targeted therapy in the treatment of renal cell carcinoma].
Miller K; Bergmann L; Albers P; Jäger E; Jakse G; Geschwend JE; Marschner N
Aktuelle Urol; 2007 Jul; 38(4):328-30. PubMed ID: 17647172
[TBL] [Abstract][Full Text] [Related]
6. [Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].
Miller K; Bergmann L; Jäger E; Jakse G; Wirth M; Keilholz U;
Aktuelle Urol; 2009 Jan; 40(1):27-30. PubMed ID: 19177318
[TBL] [Abstract][Full Text] [Related]
7. [Medical treatment of metastatic renal cell carcinoma after the approval and market entry of multitargeted tyrosine kinase inhibitors in Germany].
Bolenz C; Trojan L; Honeck P; Schöppler G; Herrmann E; Alken P; Michel MS; Häcker A
Aktuelle Urol; 2009 Jan; 40(1):31-6. PubMed ID: 19177319
[TBL] [Abstract][Full Text] [Related]
8. Early experience with targeted therapy and dendritic cell vaccine in metastatic renal cell carcinoma after nephrectomy.
Dall'Oglio MF; Sousa-Canavez JM; Tanno FY; Tiseo BC; Crippa A; Dos Reis ST; Leite KR; Srougi M
Int Braz J Urol; 2011; 37(2):180-5; discussion 185-6. PubMed ID: 21557834
[TBL] [Abstract][Full Text] [Related]
9. [Role of surgery (cytoreductive nephrectomy and metastasectomy) in the management of metastatic renal cell carcinoma: a literature review].
Arroua F; Maurin C; Carcenac A; Ragni E; Rossi D; Bastide C
Prog Urol; 2010 Dec; 20(13):1175-83. PubMed ID: 21130395
[TBL] [Abstract][Full Text] [Related]
10. Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma.
Margulis V; Matin SF; Tannir N; Tamboli P; Swanson DA; Jonasch E; Wood CG
J Urol; 2008 Jul; 180(1):94-8. PubMed ID: 18485389
[TBL] [Abstract][Full Text] [Related]
11. Against: The case for cytoreductive nephrectomy for the management of metastatic renal cell carcinoma.
Carver BS
J Urol; 2009 Sep; 182(3):833-4. PubMed ID: 19616224
[No Abstract] [Full Text] [Related]
12. Selecting patients for cytoreductive nephrectomy in advanced renal cell carcinoma: who and when.
Bex A; Powles T
Expert Rev Anticancer Ther; 2012 Jun; 12(6):787-97. PubMed ID: 22716495
[TBL] [Abstract][Full Text] [Related]
13. Pre-surgical targeted molecular therapy in renal cell carcinoma.
Margulis V; Wood CG
BJU Int; 2009 Jan; 103(2):150-3. PubMed ID: 19007359
[TBL] [Abstract][Full Text] [Related]
14. The role of surgery in advanced renal cell carcinoma: cytoreductive nephrectomy and metastasectomy.
Karam JA; Wood CG
Hematol Oncol Clin North Am; 2011 Aug; 25(4):753-64. PubMed ID: 21763966
[TBL] [Abstract][Full Text] [Related]
15. Response to sunitinib in an adult patient with rhabdoid renal cell carcinoma.
De Vincenzo F; Zucali PA; Ceresoli GL; Colombo P; Simonelli M; Lorenzi E; Perrino M; Gianoncelli L; De Sanctis R; Graziotti P; Santoro A
J Clin Oncol; 2011 Jun; 29(18):e529-31. PubMed ID: 21483010
[No Abstract] [Full Text] [Related]
16. Neoadjuvant sunitinib facilitates nephron-sparing surgery and avoids long-term dialysis in a patient with metachronous contralateral renal cell carcinoma.
Ansari J; Doherty A; McCafferty I; Wallace M; Deshmukh N; Porfiri E
Clin Genitourin Cancer; 2009 Aug; 7(2):E39-41. PubMed ID: 19692322
[TBL] [Abstract][Full Text] [Related]
17. Surgery of locally advanced and metastatic kidney cancer after tyrosine kinase inhibitors therapy: single institute experience.
De Gobbi A; Biasoni D; Catanzaro M; Nicolai N; Piva L; Stagni S; Torelli T; Procopio G; Verzoni E; Grassi P; Colecchia M; Paolini B; Spreafico C; Marchianò A; Salvioni R
Tumori; 2018 Oct; 104(5):388-393. PubMed ID: 28085177
[TBL] [Abstract][Full Text] [Related]
18. Role of cytoreductive nephrectomy in renal cell carcinoma.
Chiong E; Wood CG; Margulis V
Future Oncol; 2009 Aug; 5(6):859-69. PubMed ID: 19663735
[TBL] [Abstract][Full Text] [Related]
19. The necessity of cytoreductive nephrectomy in patients with metastatic renal cell carcinoma using antiangiogenic targeted therapy after interferon alfa-2b.
Mutlu H; Gündüz S; Büyükçelik A; Yıldız O; Uysal M; Tural D; Bozcuk H; Coşkun HŞ
Clin Genitourin Cancer; 2014 Dec; 12(6):447-50. PubMed ID: 25022784
[TBL] [Abstract][Full Text] [Related]
20. Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis.
Johannsen M; Flörcken A; Bex A; Roigas J; Cosentino M; Ficarra V; Kloeters C; Rief M; Rogalla P; Miller K; Grünwald V
Eur Urol; 2009 Jun; 55(6):1430-8. PubMed ID: 18950936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
